Pricing Log in Create free account
Friday 6 November 2026 Export PRAX’s income statement to Excel — free account

Praxis Precision Medicines, Inc.

PRAX Healthcare Biotechnology

Praxis Precision Medicines, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8.6 million, up 249.5% from fiscal 2023.

Revenue
+1,349.1%
EPS
+13.3%
Free cash flow
−43.5%

Quarter to June 2026, against a year earlier

276.75 14.16 +5.39%
Market cap
$7.3B
P/E
0.0×
Fwd P/E
−24.3×
Dividend yield
—
F-score
n/a
Altman Z
19.09
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Praxis Precision Medicines, Inc. 10-K filed Feb 19, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 8:02 AM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1, Business, against the 10-K filed Feb 28, 2025: 25 added · 8 removed · 68 modified; 1 with only figures updated; 1 moved without change

  1. Modified · COMPANY OVERVIEW

    We are a clinical-stage fully integrated, leading central nervous system, or CNS, precision neuroscience biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and both rare and more prevalent neurological disorders. We are applying genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms, using our understanding of shared biological targets and circuits in the brain. Each platform currently has multiple programs, with significant potential for additional program and indication expansion: